Impact of nonmeasurable borders and variation in cross-section counts on intravascular ultrasound measurement of atherosclerotic plaque volume

Casserly, Ivan P.; Ziada, Khaled M.; Kapadia, Samir; Schoenhagen, Paul; Tsutsui, Hiroshi; Karafa, Matthew; Shah, Amrik; Popovich, Jennifer; Nissen, Steven E.; Tuzcu, E. Murat

doi:10.1016/s0002-9149(01)02195-6

Cited by 1 publication

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, the most significant findings were found for atheroma volume in the most diseased 10-mm arterial segment (65.1 ± 27 from baseline to 59.0 ± 24.5 mm 3 at 24 months), which represents a change of -6.1 and a percentage change of -8.5% [87]. Overall, there is a relatively modest change when one considers the selection bias and the reproducibility of the methodology [88]. The effects of rosuvastatin therapy were recently studied for carotid plaque morphology and composition in moderately hypercholesterolemic patients in the ORION trial [89].…”

Section: Changes In Plaque Morphology Following Statin Usage In Humansmentioning

confidence: 94%

Pharmacotherapy of coronary atherosclerosis

Finn¹,

Kramer

Vorpahl³

et al. 2009

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Despite advances in the pharmacotherapy of atherosclerosis, the most successful agents used to treat this disease - statins - remain ineffective for the primary or secondary prevention of myocardial infarction in about two-thirds of patients. The lack of a more robust treatment effect underscores the limitations of lipid lowering alone and emphasizes the complexity of the disease and the need for targeting other critical processes. Further, despite the rapid progress in newer imaging modalities, the inability adequately to characterize lesions in individual patients beyond simple angiographic terms presents another problem. We need to be able to understand in living patients the histologic characteristics of non-flow limiting lesions and how these relate to risk for future events. Moreover, we also need to be able to modify critical elements within the atherosclerotic plaque, specifically macrophage foam cells, neoangiogenesis, necrotic core size, and fibrous cap thickness. These advancements will require newer pharmacologic agents and clinical refinements in the monitoring of treatment effects.

show abstract

Section: Changes In Plaque Morphology Following Statin Usage In Humansmentioning

confidence: 94%